| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2010PLoSO...515031L |
| P356 | DOI | 10.1371/JOURNAL.PONE.0015031 |
| P932 | PMC publication ID | 2995741 |
| P698 | PubMed publication ID | 21152022 |
| P5875 | ResearchGate publication ID | 49677714 |
| P50 | author | Aron Charles Eklund | Q28372200 |
| Andrea S Richardson | Q92038767 | ||
| Zoltan Szallasi | Q30347479 | ||
| Charles Swanton | Q30419560 | ||
| Nicolai Juul Birkbak | Q30419944 | ||
| Benjamin Haibe-Kains | Q38639014 | ||
| Christopher T. Workman | Q47502314 | ||
| P2093 | author name string | Qiyuan Li | |
| P2860 | cites work | Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer | Q24644185 |
| Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection | Q27860727 | ||
| Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. | Q51929705 | ||
| Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. | Q51935846 | ||
| Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes | Q57660183 | ||
| Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes | Q64114648 | ||
| Determination of DNA synthesis, estrogen receptors, and carcinoembryonic antigen in isolated cellular subpopulations of human breast cancer | Q68888683 | ||
| Time-dependence of hazard ratios for prognostic factors in primary breast cancer | Q74582694 | ||
| Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance | Q77809256 | ||
| Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study | Q79847215 | ||
| Predicting features of breast cancer with gene expression patterns | Q80765754 | ||
| Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer | Q29615523 | ||
| Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis | Q30004190 | ||
| Molecular characterization of the tumor microenvironment in breast cancer | Q31095898 | ||
| A gene expression bar code for microarray data | Q33300945 | ||
| Gene expression profiling of the tumor microenvironment during breast cancer progression | Q33404889 | ||
| The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data | Q33498527 | ||
| Bimodal gene expression patterns in breast cancer | Q33531526 | ||
| Optimization of the BLASTN substitution matrix for prediction of non-specific DNA microarray hybridization | Q33700155 | ||
| Effect of training-sample size and classification difficulty on the accuracy of genomic predictors | Q33892880 | ||
| A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer | Q34029272 | ||
| Tamoxifen for early breast cancer. | Q34202208 | ||
| Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. | Q36902695 | ||
| Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures | Q36955113 | ||
| A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer | Q36955150 | ||
| Current issues in ER and HER2 testing by IHC in breast cancer | Q37147777 | ||
| Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. | Q37270117 | ||
| Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer | Q37627005 | ||
| An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen | Q40313659 | ||
| Breast cancer molecular profiling with single sample predictors: a retrospective analysis | Q42467730 | ||
| Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns | Q43708523 | ||
| Commentary: hormone receptor testing in breast cancer: a distress signal from Canada | Q46262421 | ||
| The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. | Q46343921 | ||
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance | Q46689580 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunohistochemistry | Q899285 |
| P304 | page(s) | e15031 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status | |
| P478 | volume | 5 |
| Q39035017 | A novel non-parametric method for uncertainty evaluation of correlation-based molecular signatures: its application on PAM50 algorithm. |
| Q35769036 | A three-gene model to robustly identify breast cancer molecular subtypes |
| Q58772133 | Co-expressed genes enhance precision of receptor status identification in breast cancer patients |
| Q33955266 | Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q64103410 | Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers |
| Q45944833 | Machine learning approaches to decipher hormone and HER2 receptor status phenotypes in breast cancer. |
| Q33914600 | Microarray-based RNA profiling of breast cancer: batch effect removal improves cross-platform consistency. |
| Q36147185 | PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer |
| Q37690039 | PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients |
| Q33966102 | RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data |
| Q36142926 | TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. |
| Q34897615 | Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology |
| Q61805409 | pAKT pathway activation is associated with mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation |
Search more.